Determining the causes and consequences of brain amyloidosis, atrophy and cerebrovascular disease: a longitudinal amyloid-PET/MRI study of the MRC British 1946 birth cohort
Status / Stage
ActiveDates
1 July 2018 -31 July 2023
Duration (calculated)
05 years 00 monthsFunder(s)
Alzheimer's Research UKFunding Amount
£1,216,062.00Funder/Grant study page
Alzheimer's Research UKContracted Centre
University College LondonContracted Centre Webpage
Principal Investigator
Prof Jonathan Schott and Prof Nick FoxPI Contact
j.schott@ucl.ac.ukPI ORCID
0000-0003-2059-024XWHO Catergories
Understanding risk factorsUnderstanding Underlying Disease
Disease Type
Alzheimer's Disease (AD)CPEC Review Info
| Reference ID | 215 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Status / Stage | Active |
|---|---|
| Start Date | 20180701 |
| End Date | 20230731 |
| Duration (calculated) | 05 years 00 months |
| Funder/Grant study page | Alzheimer's Research UK |
| Contracted Centre | University College London |
| Contracted Centre Webpage | |
| Funding Amount | £1,216,062.00 |
Aims
The study aims to gain important insights into early brain changes in diseases like Alzheimer’s, compared to normal ageing.The volunteers have begun to have their first brain scans as part of the study and will also provide blood, urine and DNA samples.The team is using the latest PET scanning techniques to look for signs of the hallmark Alzheimer’s protein, amyloid, in the brain, as well as studying MRI scans to see structural and functional changes in the brain.They will examine how these brain images relate to the volunteers’ performance on memory and thinking assessments. This research team will also look for markers in blood and urine that could provide early indicators of Alzheimer’s and other dementias.